Skip to main content

Heart Defects, Congenital

0
Pipeline Programs
3
Companies
4
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Xeltis
XeltisNetherlands - Eindhoven
3 programs
Vascular Graft, Model COR-VG-001N/A1 trial
Xeltis Pulmonary Valved ConduitN/A1 trial
Xeltis Vascular Patch, Model COR-VP-001N/A1 trial
Active Trials
NCT02377674Completed5Est. Sep 2020
NCT03405636Withdrawn0Est. Oct 2026
NCT02377700Completed5Est. Sep 2020
Angeles Therapeutics
Angeles TherapeuticsCA - Los Angeles
1 program
HeartGPSN/A1 trial
Active Trials
NCT06175104Recruiting50Est. Dec 2027
Q Therapeutics
Q TherapeuticsUT - Salt Lake City
1 program
Xeltis Vascular Patch, Model COR-VP-001N/A

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Angeles TherapeuticsHeartGPS
XeltisXeltis Pulmonary Valved Conduit
XeltisXeltis Vascular Patch, Model COR-VP-001
XeltisVascular Graft, Model COR-VG-001

Clinical Trials (4)

Total enrollment: 60 patients across 4 trials

NCT06175104Angeles TherapeuticsHeartGPS

HeartGPS: A Study Exploring the Effects of a Psychological Intervention for Parents and Their Babies After Prenatal Cardiac Diagnosis

Start: Jul 2025Est. completion: Dec 202750 patients
N/ARecruiting
NCT03405636XeltisXeltis Pulmonary Valved Conduit

Xeltis Pulmonary Valved Conduit Safety and Performance Study

Start: Sep 2020Est. completion: Oct 20260
N/AWithdrawn
NCT02377700XeltisXeltis Vascular Patch, Model COR-VP-001

Safety and Performance of a Vascular Patch in Pediatric Patients Undergoing Bidirectional Cava-pulmonary Anastomosis

Start: Jun 2014Est. completion: Sep 20205 patients
N/ACompleted
NCT02377674XeltisVascular Graft, Model COR-VG-001

Safety and Performance of the COR-VG-001 Conduit in Pediatric Patients for Extracardiac Total Cavopulmonary Connection

Start: Oct 2013Est. completion: Sep 20205 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 60 patients
3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.